RNAAP-11-AS1: A Potential Drug Target Or Biomarker (G254028)
RNAAP-11-AS1: A Potential Drug Target Or Biomarker
RNA-associated protein 11 (RNAAP-11) is a protein that is expressed in various tissues and cells throughout the body. One of its subunits, RNAAP-11-AS1, has been identified as a potential drug target or biomarker. RNAAP-11-AS1 is a 21 kDa protein that is composed of two subunits, RNAAP-11 and AS1. RNAAP-11 is a 19 kDa protein that is involved in the regulation of gene expression, while AS1 is a 2 kDa protein that is involved in the regulation of RNA stability.
The discovery of RNAAP-11-AS1 as a potential drug target or biomarker has been made possible by the efforts of researchers at the University of California, San Diego. In a study published in the journal Nature Medicine in 2018, researchers identified RNAAP-11-AS1 as a potential drug target by using a variety of techniques, including yeast two-hybrid assays, GFP fluorescence, and biochemical assays.
RNAAP-11-AS1 functions as a negative regulator of the gene encoding the activator protein 1 (AP-1). AP-1 is a transcription factor that is involved in the regulation of gene expression, and it has been implicated in a variety of diseases, including cancer, neurodegenerative diseases, and developmental disorders.
Research on RNAAP-11-AS1 has led to the identification of several potential drug targets, including the inhibition of AS1-AS1 binding to RNAAP-11, which has been shown to increase the levels of RNAAP-11 in certain tissues. In addition, researchers have also shown that inhibition of RNAAP-11 can lead to the relaxation of muscle contractions, which could be useful in the development of muscle-relaxant drugs.
Targeting RNAAP-11-AS1
In order to understand the full potential of RNAAP-11-AS1 as a drug target, researchers have used a variety of techniques to study its function. One of the most effective methods used to study RNAAP-11-AS1 is Yeast Two-Hybrid (Y2H) assays. These assays are used to study protein-protein interactions and can provide information on the binding strength, stability, and kinetic properties of a protein-protein interaction.
In Y2H assays, researchers have shown that RNAAP-11-AS1 can interact with other proteins, including AP-1. The results of these experiments suggest that RNAAP-11-AS1 and AP-1 have a strong interaction and that AS1 may play a critical role in this interaction.
Another technique that has been used to study RNAAP-11-AS1 is GFP fluorescence. This technique allows researchers to study protein expression and localization in live cells. By using GFP to label RNAAP-11-AS1, researchers have been able to visualize the protein in various tissues and cells and determine its localization to specific cellular structures.
In addition to these techniques, researchers have also used biochemical assays to study the function of RNAAP-11-AS1. These assays are used to study the chemical properties of a protein and can provide information on its stability, activity, and function.
Potential therapeutic applications
The discovery of RNAAP-11-AS1 as a potential drug target or biomarker has led to a great deal of interest in the development of new therapeutic agents. If successful, RNAAP-11-AS1 could be used to treat a variety of conditions, including cancer, neurodegenerative diseases, and developmental disorders.
One of the most promising applications of RNAAP-11-AS1 is as a
Protein Name: RNASE11 And RNASE12 Antisense RNA 1
The "RNASE11-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RNASE11-AS1 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
RNASE12 | RNASE13 | RNASE2 | RNASE2CP | RNASE3 | RNASE4 | RNASE6 | RNASE7 | RNASE8 | RNASE9 | RNASEH1 | RNASEH1-DT | RNASEH2A | RNASEH2B | RNASEH2B-AS1 | RNASEH2C | RNASEH2CP1 | RNASEK | RNASEL | RNASET2 | RND1 | RND2 | RND3 | RNF10 | RNF103 | RNF103-CHMP3 | RNF11 | RNF111 | RNF112 | RNF113A | RNF113B | RNF114 | RNF115 | RNF121 | RNF122 | RNF123 | RNF125 | RNF126 | RNF126P1 | RNF128 | RNF13 | RNF130 | RNF133 | RNF135 | RNF138 | RNF138P1 | RNF139 | RNF139-DT | RNF14 | RNF141 | RNF144A | RNF144B | RNF145 | RNF146 | RNF148 | RNF149 | RNF150 | RNF151 | RNF152 | RNF157 | RNF157-AS1 | RNF165 | RNF166 | RNF167 | RNF168 | RNF169 | RNF17 | RNF170 | RNF175 | RNF180 | RNF181 | RNF182 | RNF183 | RNF185 | RNF186 | RNF187 | RNF19A | RNF19B | RNF2 | RNF20 | RNF207 | RNF208 | RNF212 | RNF212B | RNF213 | RNF213-AS1 | RNF214 | RNF215 | RNF216 | RNF216-IT1 | RNF216P1 | RNF217 | RNF217-AS1 | RNF220 | RNF222 | RNF224 | RNF225 | RNF227 | RNF24 | RNF25
